EANS-Adhoc: Intercell AG / Intercell and Biological E. Ltd. announce successful completion of investigational Japanese Encephalitis vaccine pivotal Phase II/III study in India

--------------------------------------------------------------------------------
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide
distribution. The issuer is solely responsible for the content of this
announcement.
--------------------------------------------------------------------------------

Research & Development

16.09.2011

* Positive results from first pivotal immunogenicity Phase II/III
trial in endemic region to prevent Japanese Encephalitis (JE) in
children * Primary study endpoint of non-inferiority of Biological
E´s investigational vaccine compared with an inactivated JE
comparator vaccine was met * Important development step towards a
modern, cell culture-derived product in endemic countries -
licensure submission to Indian DCGI expected shortly

Vienna (Austria)/Hyderabad (India), September 16, 2011 - Intercell AG
and its partner Biological E. Ltd. today announced the successful
completion of a pediatric Phase II/III study for the vaccine to
protect children from Japanese Encephalitis (JE). Analysis of the
pivotal Phase III safety and immunogenicity data showed positive
results and that the study met its primary endpoint.

The clinical study was designed to compare the immunogenicity and
safety of Biological E´s investigational cell culture-derived vaccine
with the mouse brain derived vaccine produced by the Korean Green
Cross Corporation, Korea, in a multicentre, open label, parallel,
randomised Phase II/III study design. The study, conducted across 8
study sites in India and including 456 randomized subjects, was
designed to lead to licensure in India. The vaccine is manufactured
in India by Biological E and is based on Intercell's technology,
which was successfully used to gain product licensure of the adult
vaccine in Europe, the United States, Canada, Hong Kong (IXIARO®) and
Australia (JESPECT®).

"We are very pleased to have reached this important milestone in our
collaboration with Biological E. which moves us one step closer
towards being able to provide a vaccine to protect children living in
endemic areas threatened by this terrible disease. The successful
completion of this Phase II/III study is a major step towards making
our modern cell culture-derived product available in Asia, and
supports our global territory expansion ", states Thomas Lingelbach,
Chief Executive Officer of Intercell AG.

Dr. Vijay Kumar Datla, Chairman and Managing Director of Biological
E. Limited added: "We are excited about the successful completion of
our Phase II/III clinical study which should enable us to offer this
novel and safe vaccine to combat Japanese Encephalitis not only in
India but also across Asia. There is an urgent need to respond to the
JE epidemic throughout India and Asia where large-scale immunization
is of high importance. Through our strategic partnership with
Intercell, licensure of this modern JE vaccine will allow us to
ensure the vaccine reaches those who need it most."

In March 2011, an independent data and safety monitoring board
evaluated data from 160 subjects having completed their day 7 visit
and concluded that the safety assessment was favorable, thus allowing
the study to proceed into Phase III.

In 2005, Intercell and Biological E. signed a contract for the
development, manufacturing, marketing and distribution in India and
the Indian subcontinent of Intercell's Japanese Encephalitis vaccine.
The vaccine's further regulatory approval route for other Asian
territories is expected through the World Health Organization -
Novartis will be responsible for the marketing and distribution in
these regions. Following the approval and launch of Intercell's
vaccine against Japanese Encephalitis for adult travelers and
military personnel in Europe, the USA and Australia, the development
of a vaccine to protect children in endemic areas from Japanese
Encephalitis has been a major goal of the Company.

Further inquiry note:
Intercell AG
Nina Waibel
Corporate Communications
Tel. +43 1 20620-1222
communications@intercell.com

end of announcement euro adhoc
--------------------------------------------------------------------------------

issuer: Intercell AG
Campus Vienna Biocenter 3
A-1030 Wien
phone: +43 1 20620-0
FAX: +43 1 20620-800
mail: investors@intercell.com
WWW: www.intercell.com
sector: Biotechnology
ISIN: AT0000612601
indexes: ATX Prime, ATX
stockmarkets: official market: Wien
language: English